Neuro Device for Aphasia
Trial Summary
What is the purpose of this trial?
The aim of the trial is to determine whether 75Hz transcranial alternating current stimulation (tACS) synchronized with therapeutic linguistic tasks is an effective form of therapy for post-stroke aphasia.
Will I have to stop taking my current medications?
The trial excludes participants who are on medications that increase the risk of epileptic seizures, so you may need to stop such medications. The protocol does not specify other medication restrictions.
What data supports the effectiveness of the treatment tACS for aphasia?
While there is no direct evidence for tACS in treating aphasia, similar treatments like transcranial direct current stimulation (tDCS) have shown promise in enhancing language recovery when combined with speech therapy, suggesting that non-invasive brain stimulation can support brain plasticity and language improvement.12345
Is transcranial alternating current stimulation (tACS) safe for humans?
How is the treatment tACS different from other treatments for aphasia?
Transcranial Alternating Current Stimulation (tACS) is unique because it uses alternating electrical currents to modulate brain activity, which may offer a different mechanism of action compared to the more commonly studied Transcranial Direct Current Stimulation (tDCS) that uses a constant current. This novel approach could potentially provide new benefits for language recovery in aphasia patients.511121314
Research Team
Miguel Escalon, MD, MPH
Principal Investigator
Icahn School of Medicine at Mount Sinai
Eligibility Criteria
This trial is for adults aged 18-80 who have had a stroke over 6 months ago, resulting in aphasia (difficulty with language). They must have had their first stroke affecting the left hemisphere only and be able to perform certain language tasks at a basic level. Participants should not have severe cognitive impairments or unstable psychiatric conditions, epilepsy, metal implants in the skull, heart devices like pacemakers, or be pregnant.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 75Hz transcranial alternating current stimulation (tACS) paired with therapeutic linguistic tasks
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of naming tasks and quality of life
Treatment Details
Interventions
- tACS (Neurostimulation Device)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Neuro Device S.A
Lead Sponsor
Neuro Device Group S.A.
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Collaborator